501426-61-5

Upstream product

• 501426-60-4 1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-1H-pyrazole-3-carboxylic acid 
• 895582-50-0 1-(2,4-dichlorophenyl)-4-hydroxymethyl-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid 
• 501426-48-8 1-(2,4-dichlorophenyl)-4-methyl-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid ethyl ester 
• 121-97-1 4-Methoxypropiophenone 
• 5446-18-4 2,4-dichlorophenyl hydrazine hydrochloride 

Downstream Products

• 895582-57-7 1-(2,4-dichlorophenyl)-5-(4-hydroxyphenyl)-4-methyl-1H-pyrazole-3-carboxylic acid methyl ester 
• 895582-58-8 5-[4-(tert-butyldimethyl-silanyloxy)phenyl]-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid methyl ester 
• 895582-66-8 1-(2,4-dichloro-phenyl)-4-hydroxymethyl-5-(4-(3,3,3-trifluoropropane-1-sulphonyloxy)phenyl)-1H-pyrazole-3-carboxylic acid 
• 895582-65-7 1-(2,4-dichloro-phenyl)-4-hydroxymethyl-5-(4-(3,3,3-trifluoropropane-1-sulphonyloxy)phenyl)-1H-pyrazole-3-carboxylic acid methyl ester 
• 895582-59-9 4-bromomethyl-5-[4-(tert-butyldimethyl-silanyloxy)phenyl]-1-(2,4-dichloro-phenyl)-1H-pyrazole-3-carboxylic acid methyl ester 
• 895582-60-2 1-(2,4-dichloro-phenyl)-4-hydroxymethyl-5-(4-hydroxy-phenyl)-1H-pyrazole-3-carboxylic acid methyl ester 
• 501426-63-7 2-{4-[2-(2,4-dichloro-phenyl)-4-methyl-5-(piperidin-1-ylcarbamoyl)-2H-pyrazol-3-yl]-phenoxymethyl}-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 502486-92-2 NIDA 41057 

Relevant academic research and scientific papers

THERAPEUTIC AGENTS

The present invention relates to a 1,5-diphenylpyrazole compound and its use in the treatment of obesity, psychiatric and neurological disorders, to methods for the its therapeutic use and to pharmaceutical compositions containing them.

THERAPEUTIC AGENTS

The present invention relates to a 1,5-diphenylpyrazole compound and its use in the treatment of obesity, psychiatric and neurological disorders, to methods for the its therapeutic use and to pharmaceutical compositions containing them.

THERAPEUTIC AGENTS

The present invention relates to 1,5-diphenylpyrazole compounds of formula I (A chemical formula should be inserted here - please see paper copy enclosed herewith) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: Development of central cannabinoid receptor ligands with lower lipophilicity

Exploration of the central CB1 cannabinoid receptors using positron emission tomography (PET) will allow for an understanding of the pharmacological and physiological role played by these receptors in the CNS. Current tracers are highly lipophi